临床常用铜离子螯合剂药代动力学和不良反应研究进展

doi:10.3969/j.issn.1672-5069.2015.02.033

Abstract

Tian Chi, Huang Xiameng, Wang Ting. Pharmacokinetics and adverse reactions of copper ion chelating agents[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(2): 221-224.

[1] 李光明,范建高. 肝豆状核变性的诊断与治疗进展. 实用肝脏病杂志,2012,15（6）：493-495.
[2] Alvarez HM,Xue Y,Robinson CD,et al. Tetrathiomolybdate inhibits copper trafficking proteins through metal cluster formation. Science,2010,327（5963）:331-334.
[3] Kukovetz WR,Beubler E,Kreuzig F,et al. Bioavailability and pharmacokinetics of D-penicillamine. J Rheumatol,1983,10（1）:90-94.
[4] Osman MA,Patel RB,Schuna A,et al. Reduction in oral penicillamine absorption by food,antacid,and ferrous sulfate. Clin Pharmacol Ther,1983,33（4）:465-470.
[5] Russell AS,Saetre R,Davis P,et al. A rapid,sensitive technique to assay penicillamine levels in blood and urine. J Rheumatol,1979,6（1）:15-19.
[6] Wiesner RH,Dickson ER,Carlson GL,et al. The pharmacokinetics of D-penicillamine in man. J Rheumatol Suppl,1981,7:51-55.
[7] Netter P,Bannwarth B,Pere P,et al. Clinical pharmacokinetics of D-penicillamine. Clin Pharmacokinet,1987,13（5）:317-333.
[8] 汪电雷,陶秀华,张弦,等. HPLC-UV法测定人血浆中青霉胺浓度. 中国药理学通报,2013,29（4）：585-588.
[9] Bergstrom RF,Kay RD,Wagner JG. The pharmacokinetics of penicillamine in a female mongrel dog. J Pharmacokinet Biopharm,1981,9（5）:603-621.
[10] 李桂梅.食物对口服药物的影响.中国现代药物应用,2009,3（5）：188.
[11] Nishiyama J,Kuninori T. Assay of biological thiols by a combination of high-performance liquid chromatography and postcolumn reaction with 6,6′-dithiodinicotinic acid. Anal Biochem,1984,138（1）:95-98.
[12] Yusof M,Neal R,Aykin N,et al. High performance liquid chromatography analysis of D-penicillamine by derivatization with N-（1-pyrenyl） maleimide（NPM）. Biomed Chromatogr,2000,14（8）:535-540.
[13] Zhang ZD,Baeyens W,Zhang XR,et al. HPLC determination of penicillamine in human urine applying a chemiluminescent detection system. Biomed Chromatogr,1997,11（2）:113-114.
[14] Merle U,Schaefer M,Ferenci P,et al. Clinical presentation, diagnosis and long-term outcome of Wilson’s disease:a cohort study.Gut,2007,56（1）:115-120.
[15] Medici V,Trevisan CP,D'Inca R,et al. Diagnosis and management of Wilson's disease:results of a single center experience.J Clin Gastroenterol,2006,40（10）:936-941.
[16] Rosencrantz R,Schilsky M. Wilson disease:pathogenesis and clinical considerations in diagnosis and treatment. Semin Liver Dis,2011,31（3）:245-259.
[17] Miyazaki K,Kishino S,Kobayashi M,et al. Determination of triethylenetetramine in plasma of patients by high-performance liquid chromatography. Chem Pharm Bull,1990,38（4）:1035-1038.
[18] Lu J,Poppitt SD,Othman AA,et al. Pharmacokinetics, pharmacodynamics,and metabolism of triethylenetetramine in healthy human participants:an open-label trial. J Clin Pharmacol,2010,50（6）:647-658.
[19] Shiono Y,Hayashi H,Wakusawa S,et al. Ultrastructural identification of iron and copper accumulation in the liver of a male patient with Wilson disease. Med Electron Microsc,2001,34（1）:54-60.
[20] Cho HY,Blum RA,Sunderland T,et al. Pharmacokinetic and pharmacodynamic modeling of a copper-selective chelator （TETA） in healthy adults. J Clin Pharmacol,2009,49（8）:916-928.
[21] Kodama H,Murata Y,Iitsuka T,et al. Metabolism of administered triethylene tetramine dihydrochloride in humans. Life Sci,1997,61（9）:899-907.
[22] Lu J,Chan Y,Gamble GD,et al. Triethylenetetramine and metabolites:levels in relation to copper and zinc excretion in urine of healthy volunteers and type 2 diabetic patients. Drug Metab Dispos,2007,35（2）:221-227.
[23] Cooper GJ,Phillips AR,Choong SY,et al. Regeneration of the heart in diabetes by selective copper chelation. Diabetes,2004,53（9）:2501-2508.
[24] Lee SH,Yang YJ,Kim KM,et al. Altered urinary profiles of polyamines and endogenous steroids in patients with benign cervical disease and cervical cancer. Cancer Lett,2003,201（2）:121-131.
[25] Wang Z,Hall SD,Maya JF,et al. Diabetes mellitus increases the in vivo activity of cytochrome P450 2E1 in humans. Br J Clin Pharmacol,2003,55（1）:77-85.
[26] Lu J,Chan Y,Poppitt SD,et al. Determination of triethylenetetramine（TETA） and its metabolites in human plasma and urine by liquid chromatography-mass spectrometry（LC-MS）. J Chromatogr B Analyt Technol Biomed Life Sci,2007,859（1）:62-68.
[27] Brewer GJ,Askari F,Lorincz MT,et al. Treatment of Wilson disease with ammonium tetrathiomolybdate.Arch Neurol,2006,63（4）:521-527.
[28] Saito H,Watanabe K,Sahara M,et al. Triethylene-tetramine （trien） therapy for Wilson's disease. Tohoku J Exp Med,1991,164（1）:29-35.
[29] Taylor RM,Chen Y,Dhawan A. Triethylene tetramine dihydrochloride（trientine） in children with Wilson disease:experience at king’s college hospital and review of the literature. Eur J Pediatr,2009,168（9）:1061-1068.
[30] Perry AR,Pagliuca A,Fitzsimons EJ,et al. Acquired sideroblastic anaemia induced by a copper-chelating agent. Int J Hematol,1996,64（1）:69-72.
[31] Arnon R,Calderon JF,Schilsky M,et al. Wilson disease in children: serum aminotransferases and urinary copper on triethylene tetramine dihydrochloride （trientine） treatment. J Pediatr Gastroenterol Nutr,2007,44（5）:596-602.
[32] 杨任民. 肝豆状核变性驱铜治疗的再认识.世界临床药物,2010,31（5）：257-260.
[33] 刘世军,肖红,居学海,等. 高效液相色谱荧光法测定人血浆二巯丁二酸浓度. 山东医药,2008,48（17）：28.
[34] 刘世军,肖红,居学海,等. 两种二巯丁二酸胶囊人体生物等效性研究. 白求恩军医学院学报,2007,5（5）：277-279.
[35] 刘世军,居学海,孙克明,等. 二巯丁二酸对小鼠的急性毒性作用. 中国基层医药,2007,14（8）：1315-1317.
[36] 周香雪,李洵桦,黄海威,等. 二巯基丙磺钠结合锌剂治疗肝豆状核变性方法及疗效研究. 实用医学杂志,2010,26（23）：4393-4396.
[37] 任明山,杨任民,张波,等. 二巯丙磺钠与二巯丁二酸或青霉胺治疗肝豆状核变性的比较.中国新药与临床杂志,1998,17（1）：23-25.
[38] 杨健. 肝豆状核变性的研究进展（三）. 海南医学,2013,24（8）：1172-1176.
[39] Brewer GJ,Askari F,Dick RB,et al. Treatment of Wilson's disease with tetrathiomolybdate:V. control of free copper by tetrathiomolybdate and a comparison with trientine.Transl Res,2009,154（2）:70-77.
[40] Brewer GJ. Copper-lowering therapy with tetrathiomolybdate for cancer and diseases of fibrosis and inflammation. JTraceElemExpMed,2003,16（4）:191-199.
[41] Brewer GJ,Dick RD,Grover DK,et al. Treatment of metastatic cancer with tetrathiomolybdate,an anticopper,antiangiogenic agent:phase I study.Clin Cancer Res,2000,6（1）:1-10.
[42] Wormhoudt LW,Commandeur JN,Vermeulen NP. Genetic polymorphisms of human N-acetyltransferase,cytochrome P450,glutathione-S-transferase,and epoxide hydrolase enzymes:relevance to xenobiotic metabolism and toxicity.Crit Rev Toxicol,1999,29（1）:59-124.
[43] 温兆春,王如明,孙文秀,等. 两种剂量青霉胺治疗肝豆状核变性的尿排铜曲线及其临床意义. 山东医药,2000,40（2）：29-30.

Pharmacokinetics and adverse reactions of copper ion chelating agents

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 4

Recommended Articles

Metrics

Comments

[1]	Qi Lina, Yan Mei, Guo Jianqin. Comparative analysis on laparoscopic fenestration and ultrasound-guided puncture intervention for the treatment of patients with simple hepatic cyst [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 581-584.
[2]	Wang Hua, Zhao Yaning.. Efficacy and safety of sorafenib in the treatment of patients with advanced primary liver cancer [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 936-939.
[3]	Wei Yu, Li Huahe, Zhang Xianbo. Comparison of short-term efficacy and adverse effects between entecavir and adefovir dipivoxil in the treatment of patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(3): 453-454.
[4]	Xia Dongli, Ma Hailin, Shi Xiujiang. Ozone-enriched autologous blood transfusion significantly reduce adverse reactions in chronic hepatitis C patients receiving interferon-α and ribavirin therapy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(3): 259-263.